Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
RorkesDrift...".Suggest you refrain from making all encompassing statements based on no evidence" Reporting dose escalation is a completely separate matter from the original report of a single patient at Royal Marsden. On October 19th the trials were extended to include St James in Leeds and The Christie in Manchester. What evidence do you have that not a single patient has been enrolled from those two fine institutions?
Myles McNulty
@MylesMcNulty
Jan 6
I built our 1% stake in
@avacta
before #AVCT announced its SARS-CoV-2 LFT.
I've since increased it above 1%, despite dilution.
The 100x call from 20p was largely founded on preCISION revolutionizing cancer treatment.
Thesis to be very shortly proved, right or wrong!
You are wrong to worry about the DHSC....give it a good kicking. The AVA6000 trials are run by senior medical staff and they decide if a trial has succeeded....or not. And the Americans probably have even more contempt for DHSC bureaucrats.
The UK Health Security Agency (UKHSA) said it had distributed more than 11 million rapid flow tests to pharmacies last week.
https://www.telegraph.co.uk/news/2021/12/23/christmas-testing-strategy-chaos-pharmacies-run-lateral-flow/
Codejunkie....I think LFT is worth more than support money and so does Medusa. AffiDX is only just beginning its life cycle of product development. Anyway, expecting anything out of the low liquidity AIM market in the week before Christmas is hope before experience. Come the new year and AS is probably hoping for Nasdaq before he gets slurped up for £750M.
Avacta's LFD/T's are on sale in the UK....here.
https://bioservuk.com/product/avacta-affidx-sars-cov-2-antigen-lateral-flow-test/
@MylesMcNulty
1h
Finally, #AVCT.
CE Mark for self-use in the EU is taking infinitely longer than anyone (investors and M19 /
@avacta
alike) could have ever imagined.
But at some point, it will land. That will unlock immense value, IMO, and catalyze activities in other territories.
13/16
@MylesMcNulty
1h
More importantly, AVA6000 dose escalation is due any day. No news so far should be taken as a very good sign: the last guidance from #AVCT was that mgmt was "very pleased" with the trial so far. If anything negative had occurred, we would have been updated.
14/16
@MylesMcNulty
1h
DE, and also candidate selection for the next prodrug, AVA3996, should be taken as very clear signals that #AVCT's pre CISION targeted chemotherapy platform is showing very promising signs of working in-man - at least so far.
Chemo without side effects. How to value? Man shrugging
15/16
@MylesMcNulty
2h
#AVCT remains by FAR my largest position, and being -6% YTD has hamstrung my 2021 performance severely.
Still... I have utmost conviction that
@avacta
will deliver the goods.
If pre CISION works in man... That share price could go anywhere.
Have a good break everyone!
16/16
Alec Shelbrooke MP. Is he useless? I don't know, but any outstanding ability is hidden well. Under Parliamentary News on his web site......Error: Feed has an error or is not valid. And the "Alec's Plan" web page is a model of how not to write:
"Since his re-election in December 2019, Alec has been working hard to deliver his 6-Point Plan for Elmet & Rothwell. He recently updated his plan to tackle new challenges arising from the global COVID-19 pandemic and keep pace with new opportunities in Global Britain.
Re-launching his updated plan, Alec said: “Now we have got Brexit done and come through the COVID pandemic, I want ‘My Plan for Elmet & Rothwell’ to focus on build back better and levelling-up areas that need additional investment to access new global opportunities”
With help like this AS probably feels he's shovelling s*** up a hill?
Jam tomorrow??? Yes....and lots of it. This is what Medusa 19 will be looking at....neighbourhood clinics testing for a range of ailments. A license to print money if the diagnostics can do the job properly. But it's not done overnight. Bill Gates - years ago - pointed out that people will always over-estimate what can be achieved in six months, but always under-estimate what is achieved in six years. So in four years AffiDX will probably be as common as muck.
Critics recently commented on Avacta’s rather rich AIM valuation so here’s a look.
There are more than 700 businesses listed with approximately 104 valued more than AVCT’s £300M with dozens and dozens between 2 and 3 hundred £’s.
And of the 104 - 28 are valued more than £1 billion with Hutchmed(China) leading at £4.4 billion.
Here are the top 15:
Breedon Group…£1,604 billion
Burford Capital…£1,686 billion
YouGov PLC…£1,716 billion
GB Group….£1,833 billion
Ceres Power…£1,928 billion
Impax Asset…£1,952 billion
BooHoo…£2,039 billion
Keywords Studios…£2,054 billion
Jet2…£2,221 billion
ITM Power…£2,461 billion
RWS Holdings…£2,480 billion
ASOS…£2,502 billion
Fevertree….£3,103 billion
Abcam PLC…£3,915 billion
Hutchmed(China)…£4.4 billion
Ceres is also a technology play with similar potential to Avacta. Published turnover is £32 million and it lost £17 million. Valuation….£1,928 billion.
Avacta compared to its peers? Good value I’d say.